Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
July 15, 2019 08:00 ET
|
Mereo BioPharma Group plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC...
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
June 13, 2019 08:00 ET
|
Mereo BioPharma Group plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC...
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
May 30, 2019 02:00 ET
|
Mereo BioPharma Group plc
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of...
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
May 03, 2019 12:09 ET
|
Mereo BioPharma Group plc
LONDON, May 03, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH, NASDAQ:MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that the...
Mereo BioPharma Group Plc ("Mereo" or the "Company" or the "Group") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress
April 29, 2019 02:00 ET
|
Mereo BioPharma Group plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC...
Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
April 26, 2019 08:00 ET
|
Mereo BioPharma Group plc
Mereo BioPharma Group plc("Mereo" or the "Company" or the "Group") LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based,...
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares
April 24, 2019 09:30 ET
|
Mereo BioPharma Group plc
LONDON, April 24, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that,...
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.
April 23, 2019 09:28 ET
|
Mereo BioPharma Group plc
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS...
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting
April 18, 2019 02:00 ET
|
Mereo BioPharma Group plc
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of...
Mereo BioPharma to Present at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019
March 05, 2019 08:30 ET
|
Mereo BioPharma Group plc
LONDON, March 05, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, is pleased to announce that Dr....